Sickle Cell Disease Treatment Market

Sickle Cell Disease Treatment Market by Treatment Types (Blood Transfusion, Pharmacotherapy, and Bone Marrow Transplant) and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

  • Report ID: HC-1927
  • Author: Growth Market Reports
  • Rating: 4.9
  • Total Reviews: 3
  • No. Of Pages: 214
  • Format:
  • Pub. Date: Upcoming
  • Share:

The global sickle cell disease treatment market size was valued at 1.10 billion in 2020 and is anticipated to expand at a substantial CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the increased immigration, improved healthcare, and the presence of a large population base of African origin.

Sickle Cell Disease Treatment Market

Sickle cell disease (SCD) is a genetic blood illness marked by malformed, rigid, sickle-shaped red blood cells (RBCs) caused by beta-globin gene abnormalities. The severity of the condition differs greatly from one person to another. The most common treatments for persistent SCD are hydroxyurea and blood transfusions. In general, hydroxyurea intolerance affects a substantial proportion of people. However, patients who do not have hydroxyurea resistance have minimal advantages and long-term hazards linked with safety. Sickle cell disease is a set of diseases that impair hemoglobin, the molecule that transports oxygen throughout the body. A deformed red blood cell with the shape of a sickle or crescent is found in people with this condition. Symptoms of sickle cell disease commonly appear in early childhood and continue until adolescence. Red blood cells break down prematurely as they alter the shape, which can cause anemia. The goal of sickle cell anemia treatment is to alleviate discomfort, alleviate symptoms, and prevent complications. Some adolescents and teenagers are treated with medications and blood transfusions.

Based on distinct mutations in hemoglobin genes, sickle cell anemia can be bifurcated into phenotypic variances and genotypic variances. Approximately 300,000 newborns are diagnosed with sickle cell illness every year, and around 20 to 25 million people have inherited sickle cell features worldwide. It is observed that people of African, Middle Eastern, and South Asian heritage are more likely to have sickle cell disease. Blood-borne infections, allergic responses, iron overload, and fever are all risks for patients who get blood transfusions. About 20% of sickle cell disease patients need blood transfusions to survive. Bone marrow transplant (BMT) is the only possible curative treatment; however, it is suggested to a limited number of patients.

Until 2017, hydroxyurea, marketed by Addmedica and Bristol-Myers Squibb under the names Droxia, Sicklos, and Hydrea were some of the sole drugs that the US Food and Drugs Administration (FDA) approved and are medicines commercially available for the treatment of this illness. Endari, a drug developed by Emmaus Life Sciences, was the second-ever drug approved by the FDA in July 2017 for the treatment of severe complications associated with SCD in adults and children over the age of five.

The COVID-19 pandemic had a positive impact on a few industries while the others faced a negative impact; however, the global sickle disease treatment market faced a mixed impact. The donor base demand for blood supplies was compressed down by the sudden outbreak of pandemic. The imposition of lockdown and restrictions regarding travel caused a decline in the number of donors along with the cancellation of various drives for blood donation. As per the reports by United States Blood Centres, in 2019 approximately 250,000 blood donations were missed that led to a decline in blood drive schedules. Moreover, as per the reports by American Red Cross Blood Services, in March 2020 around 50,000 blood drive schedules were cancelled or moved. However, the situation was under control and got back on track by the end of 2020 due to the approval of new regulations.

Market Trends, Drivers, Restraints, and Opportunities

  • Rising cases of sickle cell diseases across the globe along with the increasing immigration of population from Africa is expected to boost the market growth during the forecast period.
  • Improvement in healthcare services and investment made for the treatment of sickle cell disease is projected to push the market growth during the forecast period.
  • Lack of awareness among the population base coupled with the unavailability of drugs in rural areas across regions is expected to hamper the market growth.
  • High cost of treatment and low healthcare expenditure in countries with low to medium economic growth are anticipated to impede the market growth.
  • Growing research & development activities and investments made in them by the government and other several pharmaceutical companies is projected to present key opportunities for the market.

Scope of the Report

The report on the global sickle cell disease treatment market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Sickle Cell Disease Treatment Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Treatment Types (Blood Transfusion, Pharmacotherapy, and Bone Marrow Transplant)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

Emmaus Medical, Inc.; Global Blood Therapeutics, Inc.; bluebird bio, Inc.; Pfizer, Inc.; and Novartis AG.

Market Segment Insights

Pharmacotherapy segment is projected to account for a large market share

Based on treatment types, the global sickle cell disease treatment market is divided into blood transfusion, pharmacotherapy, and bone marrow transplant. The pharmacotherapy segment is projected to account for a large market share during the forecast period owing to the presence of strong pipelines and several promising drug launches. Symptomatic relief and palliative care are currently accessible treatments for sickle cell disease. Although bone marrow transplant is the sole cure for SCD, patients under the age of 16 are usually the ones who receive it due to the substantial risks involved with BMT in adults. Blood transfusions, pain relievers, and anti-inflammatories are all common treatments, as is a bone marrow transplant. The possible launch of promising pipeline candidates like voxelotor (GBT 440), crizanlizumab (SEG 101), rivipansel, and Altemia is expected to assist pharmacotherapy's rapid expansion in the sickle cell disease treatment market.

Sickle Cell Disease Treatment Market

North America is anticipated to dominate the market

On the basis of regions, the sickle cell disease treatment market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of Europe is anticipated to expand at an impressive CAGR during the forecast period. The European migrant crisis, which resulted in an increase in the immigrant population from Western Asia, South Asia, and Africa, is one of the primary factors driving the market in European countries. In 2019, the United States led the global sickle cell anemia therapy market representing with a market share of more than 32.7%, followed by France and the United Kingdom. North America is expected to maintain its dominance throughout the forecast period. This can be linked to several variables including the prospective launch of pipeline medications, greater use of innovative treatments, the presence of a large African American population, and high treatment costs in the region.

Sickle Cell Disease Treatment Market

Segments

Segments Covered in the Report

The global sickle cell disease treatment market has been segmented on the basis of

Treatment Types

  • Blood Transfusion
  • Pharmacotherapy
  • Bone Marrow Transplant

Regions

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

  • Emmaus Medical, Inc.
  • Global Blood Therapeutics, Inc.
  • bluebird bio, Inc.
  • Pfizer, Inc.
  • Novartis AG.

Competitive Landscape

Key players competing in the sickle cell disease treatment market are Emmaus Medical, Inc.; Global Blood Therapeutics, Inc.; bluebird bio, Inc.; Pfizer, Inc.; and Novartis AG. Emmaus Medical is expected to be the market leader in the coming years attributed to robust Endari sales, Followed by the approval and launch of their pipeline candidates, Altemia and voxelotor respectively, Global Blood Therapeutics and Sancilio have the potential to earn significant market share.

Drugs in the late stages of development such as Pfizer's rivipansel and Novartis' crizanlizumab have also shown promising results. Disruptive therapies such as Sevuparin from Modus Therapeutics and Sanguinate from Prolong Pharmaceuticals are expected to boost the industry. Gene therapies such as Bellicum Pharmaceutical's BPX 501, bluebird bio's Lentiglobin, and Gamida Cell's Cordin are expected to enter the sickle cell disease therapeutics market in the near future.

Sickle Cell Disease Treatment Market

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Sickle Cell Disease Treatment Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Sickle Cell Disease Treatment Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Sickle Cell Disease Treatment Market - Supply Chain
  4.5. Global Sickle Cell Disease Treatment Market Forecast
     4.5.1. Sickle Cell Disease Treatment Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Sickle Cell Disease Treatment Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Sickle Cell Disease Treatment Market Absolute $ Opportunity
5. Global Sickle Cell Disease Treatment Market Analysis and Forecast by Region
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Region
     5.2.2. Y-o-Y Growth Projections by Region
  5.3. Sickle Cell Disease Treatment Market Size and Volume Forecast by Region
     5.3.1. North America
     5.3.2. Latin America
     5.3.3. Europe
     5.3.4. Asia Pacific
     5.3.5. Middle East and Africa (MEA)
  5.4. Absolute $ Opportunity Assessment by Region
  5.5. Market Attractiveness/Growth Potential Analysis by Region
  5.6. Global Sickle Cell Disease Treatment Demand Share Forecast, 2019-2026
6. North America Sickle Cell Disease Treatment Market Analysis and Forecast
  6.1. Introduction
     6.1.1. Basis Point Share (BPS) Analysis by Country
     6.1.2. Y-o-Y Growth Projections by Country
  6.2. North America Sickle Cell Disease Treatment Market Size and Volume Forecast by Country
     6.2.1. U.S.
     6.2.2. Canada
  6.3. Absolute $ Opportunity Assessment by Country
  6.4. Market Attractiveness/Growth Potential Analysis
     6.4.1. By Country
     6.4.2. By Product Type
     6.4.3. By Application
  6.5. North America Sickle Cell Disease Treatment Demand Share Forecast, 2019-2026
7. Latin America Sickle Cell Disease Treatment Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
     7.1.3. Latin America Average Pricing Analysis
  7.2. Latin America Sickle Cell Disease Treatment Market Size and Volume Forecast by Country
      7.2.1. Brazil
      7.2.2. Mexico
      7.2.3. Rest of Latin America
   7.3. Absolute $ Opportunity Assessment by Country
  7.4. Market Attractiveness/Growth Potential Analysis
     7.4.1. By Country
     7.4.2. By Product Type
     7.4.3. By Application
  7.5. Latin America Sickle Cell Disease Treatment Demand Share Forecast, 2019-2026
8. Europe Sickle Cell Disease Treatment Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Europe Average Pricing Analysis
  8.2. Europe Sickle Cell Disease Treatment Market Size and Volume Forecast by Country
     8.2.1. Germany
     8.2.2. France
     8.2.3. Italy
     8.2.4. U.K.
     8.2.5. Spain
     8.2.6. Russia
     8.2.7. Rest of Europe
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. Market Attractiveness/Growth Potential Analysis
     8.4.1. By Country
     8.4.2. By Product Type
     8.4.3. By Application
  8.5. Europe Sickle Cell Disease Treatment Demand Share Forecast, 2019-2026
9. Asia Pacific Sickle Cell Disease Treatment Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Asia Pacific Average Pricing Analysis
  9.2. Asia Pacific Sickle Cell Disease Treatment Market Size and Volume Forecast by Country
     9.2.1. China
     9.2.2. Japan
     9.2.3. South Korea
     9.2.4. India
     9.2.5. Australia
     9.2.6. Rest of Asia Pacific (APAC)
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Market Attractiveness/Growth Potential Analysis
     9.4.1. By Country
     9.4.2. By Product Type
     9.4.3. By Application
  9.5. Asia Pacific Sickle Cell Disease Treatment Demand Share Forecast, 2019-2026
10. Middle East & Africa Sickle Cell Disease Treatment Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Middle East & Africa Average Pricing Analysis
  10.2. Middle East & Africa Sickle Cell Disease Treatment Market Size and Volume Forecast by Country
     10.2.1. Saudi Arabia
     10.2.2. South Africa
     10.2.3. UAE
     10.2.4. Rest of Middle East & Africa (MEA)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Market Attractiveness/Growth Potential Analysis
     10.4.1. By Country
     10.4.2. By Product Type
     10.4.3. By Application
  10.5. Middle East & Africa Sickle Cell Disease Treatment Demand Share Forecast, 2019-2026
11. Competition Landscape
  11.1. Global Sickle Cell Disease Treatment Market: Market Share Analysis
  11.2. Sickle Cell Disease Treatment Distributors and Customers
  11.3. Sickle Cell Disease Treatment Market: Competitive Dashboard
  11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     11.4.1. Emmaus Medical, Inc. Global Blood Therapeutics, Inc. bluebird bio, Inc. Pfizer, Inc. Novartis AG.

Segments Covered in the Report

The global sickle cell disease treatment market has been segmented on the basis of

Treatment Types

  • Blood Transfusion
  • Pharmacotherapy
  • Bone Marrow Transplant

Regions

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

  • Emmaus Medical, Inc.
  • Global Blood Therapeutics, Inc.
  • bluebird bio, Inc.
  • Pfizer, Inc.
  • Novartis AG.

Key players competing in the sickle cell disease treatment market are Emmaus Medical, Inc.; Global Blood Therapeutics, Inc.; bluebird bio, Inc.; Pfizer, Inc.; and Novartis AG. Emmaus Medical is expected to be the market leader in the coming years attributed to robust Endari sales, Followed by the approval and launch of their pipeline candidates, Altemia and voxelotor respectively, Global Blood Therapeutics and Sancilio have the potential to earn significant market share.

Drugs in the late stages of development such as Pfizer's rivipansel and Novartis' crizanlizumab have also shown promising results. Disruptive therapies such as Sevuparin from Modus Therapeutics and Sanguinate from Prolong Pharmaceuticals are expected to boost the industry. Gene therapies such as Bellicum Pharmaceutical's BPX 501, bluebird bio's Lentiglobin, and Gamida Cell's Cordin are expected to enter the sickle cell disease therapeutics market in the near future.

Sickle Cell Disease Treatment Market

Buy Report